Salesforce (NYSE:CRM – Get Free Report)’s stock had its “buy” rating reissued by equities researchers at Guggenheim in a research note issued on Thursday,Benzinga reports. They currently have a $228.00 target price on the CRM provider’s stock. Guggenheim’s price objective indicates a potential upside of 10.68% from the stock’s current price.
- The Pre-IPO Playbook: How to Cash in on Anthropic Before the Bell
A number of other equities research analysts also recently issued reports on CRM. Citigroup upped their price objective on shares of Salesforce from $187.00 to $204.00 and gave the stock a “neutral” rating in a research report on Tuesday. Barclays upgraded Salesforce from an “overweight” rating to an “overweight” rating in a report on Thursday, June 18th. BMO Capital Markets cut their price objective on Salesforce from $225.00 to $215.00 and set an “outperform” rating on the stock in a research report on Thursday, May 28th. B. Riley Financial upped their price objective on Salesforce from $205.00 to $240.00 and gave the company a “buy” rating in a research note on Thursday, May 28th. Finally, Susquehanna began coverage on Salesforce in a research note on Wednesday, July 1st. They set a “neutral” rating on the stock. Two research analysts have rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, eighteen have issued a Hold rating and three have assigned a Sell rating to the company. Based on data from MarketBeat, Salesforce has a consensus rating of “Moderate Buy” and a consensus price target of $249.49.
Check Out Our Latest Report on Salesforce
Salesforce Stock Performance
CRM opened at $206.00 on Thursday. Salesforce has a 1-year low of $146.32 and a 1-year high of $269.11. The company has a market cap of $168.71 billion, a price-to-earnings ratio of 23.79, a PEG ratio of 1.06 and a beta of 1.16. The company’s fifty day moving average price is $172.69 and its two-hundred day moving average price is $181.41. The company has a current ratio of 0.79, a quick ratio of 0.79 and a debt-to-equity ratio of 1.15.
Ad Stansberry Research
Elon Musk, Peter Thiel, Sam Altman Are Teaming Up to Back THIS New AI
Elon Musk, Peter Thiel, and Sam Altman are backing a new AI use case discovered at MIT that has already identified potential treatments for dangerous diseases.nnMcKinsey estimates this technology could be 500 times bigger than ChatGPT, while Nature projects it could add $367 trillion to the global economy.
See which stocks could benefit as Medical AI expands nationwide
